Leaderboards/CD19

CD19

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Xiaobing Wang
Unknown
927 cit.
2
Franck Morschhauser
Centre Hospitalier Universitaire de Lille
372 cit.
3
Armin Ghobadi
Washington University in St. Louis
312 cit.
4
Michael D. Jain
Moffitt Cancer Center
213 cit.
5
Simon Faissner
St. Josef-Hospital
198 cit.
6
Claire Roddie
University College London Hospitals NHS Foundation Trust
183 cit.
7
Weijia Wang
Zhongshan People's Hospital
177 cit.
8
Carlo Tur
Universitätsklinikum Erlangen
169 cit.
9
Fabian Müller
Friedrich-Alexander-Universität Erlangen-Nürnberg
168 cit.
10
Matthew J. Frank
Stanford Blood Center
165 cit.

Rising Stars Papers

1
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Cell|2024
254 cit.
2
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Nature Medicine|2024
123 cit.
3
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
The Lancet|2025
103 cit.
4
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Journal of Clinical Oncology|2024
70 cit.
5
Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome
Proceedings of the National Academy of Sciences|2024
65 cit.
6
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
New England Journal of Medicine|2024
182 cit.
7
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Annals of the Rheumatic Diseases|2024
176 cit.
8
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells
Nature Medicine|2025
55 cit.
9
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
The Lancet|2024
54 cit.
10
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
Cell|2025
53 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Katayoun Rezvani
The University of Texas MD Anderson Cancer Center
651 cit.
2
Georg Schett
Università Cattolica del Sacro Cuore
468 cit.
3
Marco Ruella
Hospital of the University of Pennsylvania
372 cit.
4
Phillip K. Darcy
The University of Melbourne
309 cit.
5
Michel Sadelain
Kettering University
261 cit.
6
Claudia Lengerke
University Children's Hospital Tübingen
229 cit.
7
Carl H. June
Parker Institute for Cancer Immunotherapy
159 cit.
8
Jérôme Galon
Inserm
156 cit.
9
Philippe Bousso
Inserm
151 cit.
10
Frederick L. Locke
University of Maryland, Baltimore
133 cit.

Emerging Leaders Papers

1
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Nature Medicine|2024
434 cit.
2
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
New England Journal of Medicine|2024
881 cit.
3
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Nature Medicine|2024
248 cit.
4
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Nature|2024
206 cit.
5
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
JAMA|2023
229 cit.
6
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Immunity|2023
159 cit.
7
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
Nature Medicine|2023
159 cit.
8
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Nature Medicine|2024
104 cit.
9
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
New England Journal of Medicine|2023
398 cit.
10
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Journal of Clinical Oncology|2023
121 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Crystal L. Mackall
National Institutes of Health
18.1k cit.
2
Edwin M. Horwitz
St. Jude Children's Research Hospital
17.6k cit.
3
Michel Sadelain
Cornell University
16.4k cit.
4
Carl H. June
Abramson Cancer Center
15.3k cit.
5
Stephan A. Grupp
University of Pennsylvania
14.2k cit.
6
Steven A. Rosenberg
Mary Ann Liebert (United States)
10.4k cit.
7
David G. Maloney
Fred Hutch Cancer Center
7.3k cit.
8
Tanya Siddiqi
City Of Hope National Medical Center
6.9k cit.
9
Cameron J. Turtle
Fred Hutch Cancer Center
6.2k cit.
10
William Y. Go
Kite (United States)
5.9k cit.

All-Time Leaders Papers

1
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Cytotherapy|2006
17.6k cit.
2
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
The Lancet|2014
2.9k cit.
3
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet|2020
2.3k cit.
4
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Journal of Clinical Investigation|2016
2.1k cit.
5
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine|2017
5.9k cit.
6
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Cell Host & Microbe|2020
2.2k cit.
7
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
New England Journal of Medicine|2018
5.6k cit.
8
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
New England Journal of Medicine|2014
5.4k cit.
9
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Nature|2017
1.8k cit.
10
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Nature Medicine|2015
1.8k cit.

All-Time Leaders Reagents

Coming soon

Indexing CD19 Reagents

Citation data for reagents in this field is currently compiling.